![]() |
Name |
2,5-Bis((3-morpholinopropyl)amino)-p-benzoquinone
|
Molecular Formula | C20H32N4O4 | |
IUPAC Name* |
2,5-bis(3-morpholin-4-ylpropylamino)cyclohexa-2,5-diene-1,4-dione
|
|
SMILES |
C1COCCN1CCCNC2=CC(=O)C(=CC2=O)NCCCN3CCOCC3
|
|
InChI |
InChI=1S/C20H32N4O4/c25-19-16-18(22-4-2-6-24-9-13-28-14-10-24)20(26)15-17(19)21-3-1-5-23-7-11-27-12-8-23/h15-16,21-22H,1-14H2
|
|
InChIKey |
JLWBELVGHBYDJT-UHFFFAOYSA-N
|
|
Synonyms |
2,5-Bis((3-morpholinopropyl)amino)-p-benzoquinone; 110052-34-1; p-Benzoquinone, 2,5-bis((3-morpholinopropyl)amino)-; 2,5-bis(3-morpholin-4-ylpropylamino)cyclohexa-2,5-diene-1,4-dione; BRN 0342334; 4-27-00-00425 (Beilstein Handbook Reference); DTXSID10149131
|
|
CAS | 110052-34-1 | |
PubChem CID | 3066340 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 392.5 | ALogp: | 0.5 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 28 | QED Weighted: | 0.396 |
Caco-2 Permeability: | -5.384 | MDCK Permeability: | 0.00001770 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.947 |
Human Intestinal Absorption (HIA): | 0.468 | 20% Bioavailability (F20%): | 1 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.927 | Plasma Protein Binding (PPB): | 73.03% |
Volume Distribution (VD): | 1.745 | Fu: | 33.12% |
CYP1A2-inhibitor: | 0.01 | CYP1A2-substrate: | 0.071 |
CYP2C19-inhibitor: | 0.017 | CYP2C19-substrate: | 0.355 |
CYP2C9-inhibitor: | 0.001 | CYP2C9-substrate: | 0.118 |
CYP2D6-inhibitor: | 0.028 | CYP2D6-substrate: | 0.897 |
CYP3A4-inhibitor: | 0.006 | CYP3A4-substrate: | 0.277 |
Clearance (CL): | 6.674 | Half-life (T1/2): | 0.349 |
hERG Blockers: | 0.104 | Human Hepatotoxicity (H-HT): | 0.282 |
Drug-inuced Liver Injury (DILI): | 0.043 | AMES Toxicity: | 0.666 |
Rat Oral Acute Toxicity: | 0.033 | Maximum Recommended Daily Dose: | 0.01 |
Skin Sensitization: | 0.967 | Carcinogencity: | 0.898 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.635 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004066 | ![]() |
0.236 | D0V4UF | ![]() |
0.286 | ||
ENC001185 | ![]() |
0.214 | D01ZSO | ![]() |
0.264 | ||
ENC000752 | ![]() |
0.211 | D0U2OO | ![]() |
0.262 | ||
ENC001289 | ![]() |
0.175 | D0F6GV | ![]() |
0.259 | ||
ENC001114 | ![]() |
0.174 | D0K0VO | ![]() |
0.258 | ||
ENC001453 | ![]() |
0.173 | D0W8SJ | ![]() |
0.256 | ||
ENC005268 | ![]() |
0.163 | D06OSM | ![]() |
0.252 | ||
ENC001201 | ![]() |
0.160 | D04FBR | ![]() |
0.243 | ||
ENC002209 | ![]() |
0.159 | D09TPF | ![]() |
0.241 | ||
ENC002331 | ![]() |
0.159 | D00EQL | ![]() |
0.239 |